NASDAQ:BOLT

Bolt Biotherapeutics Stock Forecast, Price & News

$11.78

-0.24 (-2.00 %)

(As of 07/27/2021 12:00 AM ET)

Add

Compare

Today's Range

$11.20

▼

$11.95

50-Day Range

$11.78

▼

$18.75

52-Week Range

$11.20

▼

$43.07

Volume173,211 shs

Average Volume228,187 shs

Market Capitalization$428.06 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive BOLT News and Ratings via Email

Sign-up to receive the latest news and ratings for Bolt Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.

Bolt Biotherapeutics, Inc.'s (NASDAQ:BOLT) Lock-Up Period Set To Expire on August 4th
July 28, 2021 | americanbankingnews.com

Bolt Biotherapeutics, Inc. (BOLT): Are Hedge Funds Right About This Stock?
July 20, 2021 | finance.yahoo.com

Bolt Biotherapeutics (NASDAQ:BOLT) Stock Price Up 5%
July 8, 2021 | americanbankingnews.com

Bolt Biotherapeutics (NASDAQ:BOLT) Sets New 12-Month Low at $14.43
July 6, 2021 | americanbankingnews.com

Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Peloton Interactive, Inc.
June 22, 2021 | finance.yahoo.com

Deadline Alert: Kessler Topaz Meltzer & Check, LLP Alerts Investors of Lead Plaintiff Deadline in Securities Fraud Class Action Lawsuit Against Peloton Interactive, Inc.
June 21, 2021 | finance.yahoo.com

Deadline Approaching for Peloton Interactive Investors: Berger Montague Reminds Investors of Approaching Deadline in Securities Fraud Class Action Against Peloton Interactive, Inc. (PTON); Lead Plaintiff Deadline is June 28, 2021
June 21, 2021 | finance.yahoo.com

CLASS ACTION UPDATE for PTON, PCT and FREQ: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
June 21, 2021 | finance.yahoo.com

PTON DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Peloton Interactive, Inc. of Deadline in Securities Fraud Class Action Lawsuit
June 20, 2021 | finance.yahoo.com

INVESTOR DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Peloton Interactive, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
June 18, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BOLT
Previous Symbol
CUSIP09769810
CIK354655
Webwww.boltbio.com
Phone650-665-9295
Employees65
Year FoundedN/A

Sales & Book Value

Annual Sales$230,000.00
Price / Sales1,861.14
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares36,338,000
Market Cap$428.06 million
Next Earnings Date8/12/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.75 out of 5 stars

Medical Sector

456th out of 2,218 stocks

Pharmaceutical Preparations Industry

222nd out of 869 stocks

3.5 Analyst's Opinion

Consensus Rating
Bolt Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $40.00, Bolt Biotherapeutics has a forecasted upside of 239.6% from its current price of $11.78.
Amount of Analyst Coverage
Bolt Biotherapeutics has only been the subject of 1 research reports in the past 90 days.

3.6 Community Rank

Outperform Votes
Bolt Biotherapeutics has received 64 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Bolt Biotherapeutics has received 25 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Bolt Biotherapeutics has received 71.91% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Bolt Biotherapeutics and other stocks. Vote “Outperform” if you believe BOLT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BOLT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Bolt Biotherapeutics does not currently pay a dividend.
Dividend Growth
Bolt Biotherapeutics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bolt Biotherapeutics insiders have not sold or bought any company stock.
Percentage Held by Institutions
86.68% of the stock of Bolt Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Bolt Biotherapeutics are expected to decrease in the coming year, from ($2.08) to ($2.50) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bolt Biotherapeutics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bolt Biotherapeutics is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Bolt Biotherapeutics (NASDAQ:BOLT) Frequently Asked Questions

Is Bolt Biotherapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bolt Biotherapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Bolt Biotherapeutics stock.
View analyst ratings for Bolt Biotherapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Bolt Biotherapeutics?

Wall Street analysts have given Bolt Biotherapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Bolt Biotherapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Bolt Biotherapeutics' next earnings date?

Bolt Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for Bolt Biotherapeutics.

How were Bolt Biotherapeutics' earnings last quarter?

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) announced its quarterly earnings data on Thursday, May, 13th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.64) by $0.22.
View Bolt Biotherapeutics' earnings history.

What price target have analysts set for BOLT?

4 Wall Street analysts have issued 1 year price objectives for Bolt Biotherapeutics' stock. Their forecasts range from $33.00 to $45.00. On average, they anticipate Bolt Biotherapeutics' stock price to reach $40.00 in the next twelve months. This suggests a possible upside of 239.6% from the stock's current price.
View analysts' price targets for Bolt Biotherapeutics or view top-rated stocks among Wall Street analysts.

Who are Bolt Biotherapeutics' key executives?

Bolt Biotherapeutics' management team includes the following people:

Dr. Randall C. Schatzman, CEO & Director (Age 66, Pay $706.05k)
Mr. William P. Quinn, Chief Financial Officer (Age 50, Pay $454.69k)
Dr. David Dornan Ph.D., Chief Scientific Officer (Age 43, Pay $422.5k)
Mr. Grant Yonehiro, Chief Bus. Officer (Age 57, Pay $434.07k)
Dr. Edith A. Perez M.D., Chief Medical Officer (Age 64, Pay $607.49k)
Dr. Edgar G. Engleman, Founder, Sec. & Director (Age 75)
Mr. Wesley Burwell, VP & Head of HR

Who are some of Bolt Biotherapeutics' key competitors?

Some companies that are related to Bolt Biotherapeutics include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of BOLT's competitors.

What other stocks do shareholders of Bolt Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bolt Biotherapeutics investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Ampio Pharmaceuticals (AMPE), Apellis Pharmaceuticals (APLS), Aquantia (AQ) and Aquinox Pharmaceuticals (AQXP).

When did Bolt Biotherapeutics IPO?

(BOLT) raised $150 million in an initial public offering (IPO) on Friday, February 5th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Stifel and Guggenheim Securities served as the underwriters for the IPO.

What is Bolt Biotherapeutics' stock symbol?

Bolt Biotherapeutics trades on the NASDAQ under the ticker symbol "BOLT."

When does the company's lock-up period expire?

Bolt Biotherapeutics' lock-up period expires on Wednesday, August 4th. Bolt Biotherapeutics had issued 11,500,000 shares in its IPO on February 5th. The total size of the offering was $230,000,000 based on an initial share price of $20.00. After the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

How do I buy shares of Bolt Biotherapeutics?

Shares of BOLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bolt Biotherapeutics' stock price today?

One share of BOLT stock can currently be purchased for approximately $11.78.

How much money does Bolt Biotherapeutics make?

Bolt Biotherapeutics has a market capitalization of $428.06 million and generates $230,000.00 in revenue each year. The company earns $-60,730,000.00 in net income (profit) each year or ($22.26) on an earnings per share basis.

How many employees does Bolt Biotherapeutics have?

Bolt Biotherapeutics employs 65 workers across the globe.

What is Bolt Biotherapeutics' official website?

The official website for Bolt Biotherapeutics is www.boltbio.com.

Where are Bolt Biotherapeutics' headquarters?

Bolt Biotherapeutics is headquartered at 900 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063.

How can I contact Bolt Biotherapeutics?

Bolt Biotherapeutics' mailing address is 900 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The company can be reached via phone at 650-665-9295 or via email at [email protected]

This page was last updated on 7/28/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here